SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers

SIMPLE SUMMARY: More and more relapsing or refractory pediatric cancers are described to present hypoxic features linked to a worse outcome. Therefore, the aim of our phase I study RAPIRI was the targeting of the central node mTor/HIF-1α with rapamycin plus irinotecan and determine the appropriated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jannier, Sarah, Kemmel, Véronique, Sebastia Sancho, Consuelo, Chammas, Agathe, Sabo, Amelia-Naomie, Pencreach, Erwan, Farace, Françoise, Chenard, Marie Pierre, Lhermitte, Benoit, Geoerger, Birgit, Aerts, Isabelle, Frappaz, Didier, Leblond, Pierre, André, Nicolas, Ducassou, Stephane, Corradini, Nadège, Bertozzi, Anne Isabelle, Guérin, Eric, Vincent, Florence, Velten, Michel, Entz-Werle, Natacha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656302/
https://www.ncbi.nlm.nih.gov/pubmed/33092063
http://dx.doi.org/10.3390/cancers12103051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656302/
https://www.ncbi.nlm.nih.gov/pubmed/33092063
http://dx.doi.org/10.3390/cancers12103051

Ejemplares similares